CVKD Stock Analysis: Buy, Sell, or Hold?
CVKD - Cadrenal Therapeutics, Inc. Common Stock
$1.75
0.21 (13.64%)
▲
5d:
+11.46%
30d:
-12.94%
90d:
-62.77%
HOLD
LOW Confidence
Analysis Updated: Aug 31, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When CVKD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CVKD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CVKD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CVKD is currently trading at $1.75, which is considered fair relative to its 30-day fair value range of $1.64 to $2.02.
Technical Outlook: Technically, CVKD is in a strong downtrend. Immediate support is located at $1.46, while resistance sits at $2.29. The stock is showing strong short-term momentum, up 13.6% recently.
Market Sentiment: CVKD scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.00 (+700.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CVKD is in a strong downtrend. Immediate support is located at $1.46, while resistance sits at $2.29. The stock is showing strong short-term momentum, up 13.6% recently.
Market Sentiment: CVKD scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.00 (+700.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.64 -
$2.02
Company Quality Score
59/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+13.6%)
- BULLISH: Trading 700.0% below Wall St target ($14.00)
- CAUTION: Bottoming setup, but lagging the sector by 13% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.64 -
$2.02
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.46
Resistance Level
$2.29
Current Trend
Strong Downtrend
Technical data as of
Aug 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.51
Wall Street Target
$14.00
(+700.0%)
Share & Embed Analysis
Last updated: August 31, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVKD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 39 SELL |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 25 SELL |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 37 SELL |
